News: API Australian Pharmaceutical Industries Posts FY NPAT Of $56.6 Mln, page-7

well a fair bit has changed particularly in the past financial year.
obviously acquisitions and growth debt driven 50mil to 200mil
it does increase risk
but if EPS jumps to around 13 cents, than its a game changer
i don’t know enough about this strategy some due diligence will be needed
from memory I left this during a restructuring period.
it’s now entered into growth again. This might need a few quarterlies before API can capitalise on these opportunities.
i could go half in now, the other half in 12 months. I’d get pretty excited to watch EPS jump, I imagine this is on the radar of others